查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585838

支氣管炎治療藥物市場：按藥物類型、應用分類 - 全球預測 2025-2030

Bronchitis Drugs Market by Drug Type (Anti-inflammatory Drugs, Antibiotics, Bronchodilators), Application (Acute Bronchitis, Chronic Bronchitis) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年支氣管炎治療藥物市值為15.4億美元，預計到2024年將達到16.8億美元，複合年成長率為9.74%，預計到2030年將達到29.6億美元。

支氣管炎藥物市場的特點是其範圍包括專門用於緩解症狀和治療急慢性支氣管炎的非處方藥和處方藥。其中包括抗生素、發炎、支氣管擴張劑、止咳藥和其他形式的藥物，這些藥物對於減少發炎和控制患者支氣管症狀非常重要。這些藥物的使用在解決呼吸問題（從即時緩解症狀到長期管理）方面發揮著重要作用，凸顯了它們在醫療保健方面的需求。最終用途主要是在醫院、診所和家庭護理機構中常規使用這些藥物。呼吸系統疾病發病率的增加、污染水平的上升導致支氣管炎患者的增加以及更容易患呼吸系統疾病的老年人口的增加推動了市場的成長。最近的趨勢凸顯了對高效能、速效藥物的需求，以及對植物來源或草藥治療日益成長的興趣，提供了新的潛在機會。公司可以透過投資個人化醫療等創新解決方案的研發、利用生物技術和基因組學的進步以及探索植物來源化合物來增加資本。然而，抗生素抗藥性危機、潛在副作用以及新興市場缺乏意識等挑戰可能會阻礙成長。監管障礙和嚴格的核准流程是主要限制因素，需要可靠的資料和測試。臨床試驗以及與醫療機構合作開發具有成本效益的藥物可以解決這些障礙。此外，遠端醫療和人工智慧健康監測等數位健康技術可能為患者參與和藥物管理提供新途徑，反映了市場的動態本質。總體而言，創新的機會在於開發環保產品、加強藥物輸送系統以及擴大服務欠缺地區獲得支氣管炎治療的機會，同時支持永續的業務成長，跟上不斷變化的監管環境和以患者為中心的護理非常重要。

主要市場統計
基準年[2023] 15.4億美元
預測年份 [2024] 16.8億美元
預測年份 [2030] 29.6億美元
複合年成長率（%） 9.74%

市場動態：揭示快速發展的支氣管炎藥物市場的關鍵市場洞察

供應和需求的動態交互作用正在改變支氣管炎藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 老年人口增加導致呼吸系統疾病增加
    • 吸煙等不健康習慣增加
    • 工業擴張導致慢性支氣管炎發生率增加
  • 市場限制因素
    • 生產支氣管炎治療藥物投資成本高
  • 市場機會
    • 政府和私人組織增加對支氣管炎治療方法研發的投資
    • 製造商之間策略聯盟的增加
  • 市場挑戰
    • 核准流程規定嚴格、程序複雜

波特五力：駕馭支氣管炎藥物市場的策略工具

波特的五力架構是了解支氣管炎治療藥物市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對支氣管炎治療藥物市場的影響

外部宏觀環境因素在塑造支氣管炎治療藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解支氣管炎治療藥物市場的競爭狀況

支氣管炎治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣支氣管炎治療市場供應商的績效評估

FPNV 定位矩陣是評估支氣管炎治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪支氣管炎治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對支氣管炎治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老化社會呼吸系統疾病發生率上升
      • 吸煙等不健康習慣在人群中不斷增加
      • 工業擴張增加慢性支氣管炎發生率
    • 抑制因素
      • 生產支氣管炎治療藥物的投資成本很高。
    • 機會
      • 政府和私人組織增加對支氣管炎治療方法研發的投資
      • 擴大製造商之間的策略合作
    • 任務
      • 核准流程規定嚴格、程序複雜
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 依藥物類型分類的支氣管炎治療藥物市場

  • 發炎藥
  • 抗生素
  • 支氣管擴張劑
  • 黏液溶解藥

第7章支氣管炎治療藥物市場：依應用分類

  • 急性支氣管炎
  • 慢性支氣管炎

第8章 北美和南美支氣管炎治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區支氣管炎治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲支氣管炎治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alembic Pharmaceuticals Ltd.
  • Apotex Inc.
  • Boehringer Ingelheim International GmbH
  • DLC Laboratories, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Jamp Pharma Corporation
  • Marlex Pharmaceuticals, Inc.
  • Novartis International AG
  • Sandoz AG
  • Sanofi SA
  • Sun Pharmaceutical Industries, Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA05239

The Bronchitis Drugs Market was valued at USD 1.54 billion in 2023, expected to reach USD 1.68 billion in 2024, and is projected to grow at a CAGR of 9.74%, to USD 2.96 billion by 2030.

The bronchitis drugs market is characterized by its scope, which encompasses over-the-counter and prescription medications tailored to alleviate symptoms and treat acute and chronic bronchitis. The scope extends to various forms of drugs such as antibiotics, anti-inflammatory drugs, bronchodilators, and cough suppressants, crucial for reducing inflammation and managing bronchial symptoms in patients. The application of these medications plays a vital role in addressing respiratory issues, from immediate symptom relief to long-term management, highlighting their necessity in healthcare. End-use is primarily within hospitals, clinics, and home care settings where these medications are routinely prescribed. Market growth is propelled by increasing incidences of respiratory diseases, rising pollution levels contributing to higher bronchitis cases, and a growing geriatric population prone to respiratory conditions. Recent trends emphasize the demand for efficient and rapid-acting drugs alongside a burgeoning interest in plant-based or herbal treatments, offering new potential opportunities. Companies could capitalize by investing in R&D for innovative solutions like personalized medicine, leveraging advances in biotechnology and genomics, or exploring plant-derived compounds. However, challenges such as the antibiotic resistance crisis, potential side effects, and the lack of awareness in emerging markets could impede growth. Regulatory hurdles and stringent approval processes pose significant limitations, requiring robust data and trials. Collaborations with healthcare institutions for clinical studies and the development of cost-effective medications can address such barriers. Additionally, digital health technologies including telemedicine and AI-driven health monitoring could offer novel avenues for patient engagement and medication management, reflecting the market's dynamic nature. Overall, innovation opportunities lie in developing eco-friendly products, enhancing drug delivery systems, and expanding access to bronchitis treatments in underserved regions, while staying abreast of evolving regulatory landscapes and patient-centric care models for sustainable business growth.

KEY MARKET STATISTICS
Base Year [2023] USD 1.54 billion
Estimated Year [2024] USD 1.68 billion
Forecast Year [2030] USD 2.96 billion
CAGR (%) 9.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchitis Drugs Market

The Bronchitis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of respiratory problems in the growing elderly population
    • Growing unhealthy habits such as smoking among the population
    • Expansion of industries increases the incidence of chronic bronchitis
  • Market Restraints
    • High cost of investment in production of bronchitis drugs
  • Market Opportunities
    • Increasing investments from government and private organizations for research and development of bronchitis drugs
    • Growing strategic collaborations among manufacturers
  • Market Challenges
    • Strict regulations and cumbersome procedure in the approval process

Porter's Five Forces: A Strategic Tool for Navigating the Bronchitis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchitis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchitis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchitis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchitis Drugs Market

A detailed market share analysis in the Bronchitis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchitis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchitis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchitis Drugs Market

A strategic analysis of the Bronchitis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchitis Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Ltd., Apotex Inc., Boehringer Ingelheim International GmbH, DLC Laboratories, Inc., Dr. Reddy's Laboratories Ltd., Fresenius Kabi, GlaxoSmithKline Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Jamp Pharma Corporation, Marlex Pharmaceuticals, Inc., Novartis International AG, Sandoz AG, Sanofi S.A., Sun Pharmaceutical Industries, Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bronchitis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Anti-inflammatory Drugs, Antibiotics, Bronchodilators, and Mucolytics.
  • Based on Application, market is studied across Acute Bronchitis and Chronic Bronchitis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of respiratory problems in the growing elderly population
      • 5.1.1.2. Growing unhealthy habits such as smoking among the population
      • 5.1.1.3. Expansion of industries increases the incidence of chronic bronchitis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of investment in production of bronchitis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments from government and private organizations for research and development of bronchitis drugs
      • 5.1.3.2. Growing strategic collaborations among manufacturers
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulations and cumbersome procedure in the approval process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchitis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anti-inflammatory Drugs
  • 6.3. Antibiotics
  • 6.4. Bronchodilators
  • 6.5. Mucolytics

7. Bronchitis Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Acute Bronchitis
  • 7.3. Chronic Bronchitis

8. Americas Bronchitis Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Bronchitis Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Bronchitis Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alembic Pharmaceuticals Ltd.
  • 2. Apotex Inc.
  • 3. Boehringer Ingelheim International GmbH
  • 4. DLC Laboratories, Inc.
  • 5. Dr. Reddy's Laboratories Ltd.
  • 6. Fresenius Kabi
  • 7. GlaxoSmithKline Pharmaceuticals Ltd.
  • 8. Glenmark Pharmaceuticals Ltd.
  • 9. Jamp Pharma Corporation
  • 10. Marlex Pharmaceuticals, Inc.
  • 11. Novartis International AG
  • 12. Sandoz AG
  • 13. Sanofi S.A.
  • 14. Sun Pharmaceutical Industries, Ltd.
  • 15. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BRONCHITIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHITIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BRONCHITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BRONCHITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHITIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHITIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ACUTE BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. BRONCHITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. BRONCHITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023